Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms [PDF]
Toxins, 2020 The phospholipase A2 (PLA2) inhibitor Varespladib (LY315920) and its orally bioavailable prodrug, methyl-Varespladib (LY333013) inhibit PLA2 activity of a wide variety of snake venoms.
José Maria Gutierrez +2 more
exaly +10 more sources
Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib) [PDF]
Toxins, 2018 Snakebite is a global tropical disease that has long had huge implications for human health and well-being. Despite its long-standing medical importance, it has been the most neglected of tropical diseases.
Mátyás A. Bittenbinder +7 more
doaj +9 more sources
Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of Micrurus fulvius (Eastern Coral Snake) Venom [PDF]
Toxins, 2018 There is a clear, unmet need for effective, lightweight, shelf-stable and economical snakebite envenoming therapies that can be given rapidly after the time of a snake’s bite and as adjuncts to antivenom therapies in the hospital setting. The sPLA2
Matthew R. Lewin +6 more
doaj +6 more sources
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation [PDF]
Toxins, 2016 Snakebite remains a neglected medical problem of the developing world with up to 125,000 deaths each year despite more than a century of calls to improve snakebite prevention and care.
Stephen Samuel, Lewin Mr
exaly +6 more sources
Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920) [PDF]
Scientific Reports, 2019 The World Health Organization recently listed snakebite envenoming as a Neglected Tropical Disease, proposing strategies to significantly reduce the global burden of this complex pathology by 2030.
Guilherme Henrique Marchi Salvador +2 more
exaly +8 more sources
Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes [PDF]
Toxins, 2022 The availability of effective, reliably accessible, and affordable treatments for snakebite envenoming is a critical and long unmet medical need. Recently, small, synthetic toxin-specific inhibitors with oral bioavailability used in conjunction with ...
Bryan Fry, Lewin Mr, Rebecca W Carter
exaly +4 more sources
Acta Tropica, 2022 The venoms of Asiatic kraits (Bungarus spp.) contain various neurotoxic phospholipases A(2) (beta-bungamtoxins) which can irreversibly damage motor nerve terminals, resulting in rapidly fatal suffocation by respiratory muscle paralysis or oral airway ...
Kae Yi Tan, Choo Hock Tan
exaly +6 more sources
sPLA2-IIA Augments Oxidized LDL-Induced MCP-1 Expression in Vitro Through Activation of Akt
Cellular Physiology and Biochemistry, 2015 Background/Aims: Group IIA secretory phospholipase A2 (sPLA2-IIA) has an important role in atherosclerosis. In this study, we explored whether sPLA2-IIA overexpression could promote atherosclerosis in normal environment alone or with other inflammatory ...
Yongjun Guo +4 more
doaj +2 more sources
Biochimie, 2023 Varespladib (LY315920) is a potent inhibitor of human group IIA phospholipase A2 (PLA2) originally developed to control inflammatory cascades of diseases associated with high or dysregulated levels of endogenous PLA2. Recently, varespladib was also found
Guilherme Henrique Marchi Salvador +2 more
exaly +2 more sources
Biochimica Et Biophysica Acta - General Subjects, 2021 The treatment for snakebites is early administration of antivenom, which can be highly effective in inhibiting the systemic effects of snake venoms, but is less effective in the treatment of extra-circulatory and local effects.
Borges Rj +2 more
exaly +2 more sources